Inflammatory bowel diseases (IBDs) are characterized by chronic inflammatory disorders
that are a result of an abnormal immune response mediated by a cytokine storm and …

Despite recent advances in the understanding of the pathogenesis of inflammatory bowel
diseases (IBD) and advent of multiple targeted therapies, approximately one-third of patients …

Background The prevalence of inflammatory bowel disease (IBD) is rising globally. In
Germany, these conditions affect 0.7% of the population, or approximately 600 000 patients …

Inflammatory bowel disease (IBD) is a lifelong inflammatory immune mediated disorder,
encompassing Crohn's disease (CD) and ulcerative colitis (UC); however, the cause and …

A growing number of patients with Crohn's disease and ulcerative colitis have disease that is
refractory to multiple advanced therapies, have undergone multiple surgeries and require …

Abstract Background and Aims Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, was
well-tolerated and efficacious in the phase 2b VIBRATO study in participants with moderate …

Abstract Background Inflammatory bowel diseases (IBDs) pose significant challenges in
terms of treatment non‐response, necessitating the development of novel therapeutic …

Long-term use of conventional drugs to treat inflammatory bowel diseases (IBD) and colitis-
associated cancer (CAC) has an adverse impact on the human immune system and easily …

RESULTS: Nineteen patients were treated with UST for IMC refractory to steroids plus
infliximab (57.9%) and/or vedolizumab (94.7%). Most of them had grade≥ 3 diarrhea …

Group 3 innate lymphoid cells (ILC3s) are abundant in the developing or healthy intestine to
critically support tissue homeostasis in response to microbial colonization. However …